Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
16-week randomized double-blind trial of roflumilast in COPD
2011-000582-13Phase 3Completed
- Sponsor
- Takeda
- Start
- Oct 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Roflumilast arm with Placebo arm (2 arms). Primary endpoint: CD8+ inflammatory cells in bronchial biopsy (submucosa). Started Oct 2011; status: completed.
02
Drugs
roflumilast
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2011-000582-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000582-13.